Literature DB >> 16957870

Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms.

Ahmed E Enayetallah1, Richard A French, David F Grant.   

Abstract

Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with a C-terminal epoxide hydrolase activity and an N-terminal phosphatase activity. Arachidonic acid epoxides, previously suggested to be involved in apoptosis, oncogenesis and cell proliferation, are generated by cytochrome P450 epoxygenases and are good substrates of the sEH C-terminal domain. In addition, the N-terminal phosphatase domain hydrolyzes isoprenoid mono- and pyrophosphates, which are involved in cell signaling and apoptosis. Here we provide a comprehensive analysis of the distribution of sEH, CYP2C8, 2C9 and 2J2 in human neoplastic tissues using tissue micro-arrays. The human neoplastic tissue micro-arrays provide a well-controlled side by side analysis of a wide array of neoplastic tissues and their surrounding normal tissue controls. Many of the neoplastic tissues showed altered expression of these enzymes as compared to normal tissues. Altered expression was not limited to the neoplastic tissues but also found in the surrounding non-neoplastic tissues. For example, sEH expression in renal and hepatic malignant neoplasms and surrounding non-neoplastic tissues was found to be significantly decreased, whereas expression was found to be increased in seminoma as compared to normal tissues. Our study warrants further investigation of the role of altered expression of these enzymes in neoplastic tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16957870     DOI: 10.1007/s10735-006-9050-9

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  45 in total

1.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

2.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Authors:  D Dai; D C Zeldin; J A Blaisdell; B Chanas; S J Coulter; B I Ghanayem; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-10

3.  Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.

Authors:  Primo N Lara; Lisa Y Law; John J Wright; Paul Frankel; Przemyslaw Twardowski; Heinz Josef Lenz; Derick H M Lau; Tomoya Kawaguchi; Paul H Gumerlock; James H Doroshow; David R Gandara
Journal:  Anticancer Drugs       Date:  2005-03       Impact factor: 2.248

4.  Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.

Authors:  S J London; A K Daly; J B Leathart; W C Navidi; J R Idle
Journal:  Pharmacogenetics       Date:  1996-12

5.  Stimulation of prostaglandin G/H synthase-2 expression by arachidonic acid monoxygenase product, 14,15-epoxyeicosatrienoic acid.

Authors:  K G Peri; D R Varma; S Chemtob
Journal:  FEBS Lett       Date:  1997-10-27       Impact factor: 4.124

6.  Involvement of microsomal cytochrome P450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegafur in human liver.

Authors:  T Komatsu; H Yamazaki; N Shimada; S Nagayama; Y Kawaguchi; M Nakajima; T Yokoi
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

7.  A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.

Authors:  Grace K Dy; Laura M Bruzek; Gary A Croghan; Sumithra Mandrekar; Charles Erlichman; Prema Peethambaram; Henry C Pitot; Lorelei J Hanson; Joel M Reid; Alfred Furth; Shinta Cheng; Robert E Martell; Scott H Kaufmann; Alex A Adjei
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

8.  The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase.

Authors:  Annette Cronin; Sherry Mowbray; Heike Dürk; Shirli Homburg; Ingrid Fleming; Beate Fisslthaler; Franz Oesch; Michael Arand
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

9.  [Expression of cytochrome P450 enzymes in human nasopharyngeal carcinoma and non-cancerous nasopharynx tissue].

Authors:  Ju-Hong Jiang; Wei-Hua Jia; Hai-De Qin; Hui Liang; Zhi-Gang Pan; Yi-Xin Zeng
Journal:  Ai Zheng       Date:  2004-06

10.  Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase.

Authors:  M F Moghaddam; D F Grant; J M Cheek; J F Greene; K C Williamson; B D Hammock
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

View more
  34 in total

Review 1.  EET signaling in cancer.

Authors:  Dipak Panigrahy; Emily R Greene; Ambra Pozzi; Dao Wen Wang; Darryl C Zeldin
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

2.  Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.

Authors:  Paula Vainio; Santosh Gupta; Kirsi Ketola; Tuomas Mirtti; John-Patrick Mpindi; Pekka Kohonen; Vidal Fey; Merja Perälä; Frank Smit; Gerald Verhaegh; Jack Schalken; Kalle A Alanen; Olli Kallioniemi; Kristiina Iljin
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Eicosanoid signaling in carcinogenesis of colorectal cancer.

Authors:  Yuxin Wang; Weicang Wang; Katherine Z Sanidad; Pei-An Shih; Xinfeng Zhao; Guodong Zhang
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

4.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

5.  t-AUCB, an improved sEH inhibitor, suppresses human glioblastoma cell growth by activating NF-κB-p65.

Authors:  Junyang Li; Hongyi Liu; Biao Xing; Yanzhe Yu; Hui Wang; Gong Chen; Bing Gu; Guofeng Zhang; Dong Wei; Peiyuan Gu; Meng Li; Weixing Hu
Journal:  J Neurooncol       Date:  2012-03-02       Impact factor: 4.130

6.  Lysophosphatidic acids are new substrates for the phosphatase domain of soluble epoxide hydrolase.

Authors:  Ami Oguro; Susumu Imaoka
Journal:  J Lipid Res       Date:  2012-01-03       Impact factor: 5.922

7.  Soluble epoxide hydrolase deficiency inhibits dextran sulfate sodium-induced colitis and carcinogenesis in mice.

Authors:  Wanying Zhang; Haonan Li; Hua Dong; Jie Liao; Bruce D Hammock; Guang-Yu Yang
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

Review 8.  Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.

Authors:  Dipak Panigrahy; Arja Kaipainen; Emily R Greene; Sui Huang
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

Review 9.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

10.  Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2.

Authors:  Hiromasa Tanaka; Shizuo G Kamita; Nicola M Wolf; Todd R Harris; Zhaoju Wu; Christophe Morisseau; Bruce D Hammock
Journal:  Biochim Biophys Acta       Date:  2007-12-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.